4D Molecular Therapeutics, Inc. (FDMT)

Market Cap	778.39M +129.6%
Revenue (ttm)	92.01M +278,712.1%
Net Income	-179.18M
EPS	-2.77
Shares Out	55.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	635,596
Open	14.25
Previous Close	14.55
Day's Range	14.10 - 15.04
52-Week Range	5.97 - 15.03
Beta	2.69
Analysts	Buy
Price Target	29.10 (+106.53%)
Earnings Date	Aug 13, 2026

About FDMT

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 196
• Stock Exchange: NASDAQ
• Ticker Symbol: FDMT

Financial Performance

In 2025, 4D Molecular Therapeutics's revenue was $85.21 million, an increase of 230194.59% compared to the previous year's $37,000. Losses were -$140.11 million, -12.90% less than in 2024.

Analyst Summary

According to 12 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price target is $29.1, which is an increase of 106.53% from the latest price.

Price Target

$29.1

(106.53% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 18, 2026

Data Sources Report a data error